Delving into the Latest Updates on Talacotuzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

IL-13 MAb-CSL, TAL

+ [7]

Target

CD123

Action

inhibitors, stimulants

Mechanism

CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Natural killer cells stimulants(Natural killer cells stimulants)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [1]

Active Indication

Acute Myeloid LeukemiaSystemic Lupus Erythematosus

Inactive Indication

CD123 Positive Acute Myeloid LeukemiaMyelodysplastic Syndromes

Originator Organization

CSL Ltd.

Active Organization

CSL Ltd.

Janssen Global Services LLC

Inactive Organization

Janssen Research & Development LLC

Janssen Biotech, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 146656H

Source: *****

Sequence Code 146663L

Source: *****

The purpose of this study is to assess the safety and tolerability of JNJ-56022473 following multiple subcutaneous (SC) study agent administrations in subjects with Systemic Lupus Erythematosus (SLE) and to determine whether premedication with corticosteroids is required to improve the tolerability of SC JNJ-56022473.

Start Date30 Jun 2017

Sponsor / Collaborator

Janssen Research & Development LLC

NCT03011034

/ CompletedPhase 2

A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

The main purpose of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent participants with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) whose disease has relapsed during treatment with or is refractory to Erythropoiesis-Stimulating Agent (ESAs).

Start Date14 Feb 2017

Sponsor / Collaborator

Janssen Research & Development LLC

EUCTR2016-000327-10-DE

/ Not yet recruitingPhase 2

SINGLE AGENT JNJ-56022473 IN MDS AND AML PATIENTS FAILING HYPOMETHYLATING AGENT BASED THERAPY - SAMBA-trial

Start Date03 Nov 2016

Sponsor / Collaborator-

100 Clinical Results associated with Talacotuzumab

Login to view more data

100 Translational Medicine associated with Talacotuzumab

Login to view more data

100 Patents (Medical) associated with Talacotuzumab

Login to view more data

151

Literatures (Medical) associated with Talacotuzumab

01 Feb 2025·International Journal of Biological Macromolecules

Fabrication of ethylcellulose/technical alkaline lignin composite film with high anticorrosion performance in NaCl, HCl, and KOH solutions

Article

Author: Li, Hai-Chao ; Xu, Feng ; Li, De-Qiang ; Chen, Sheng ; Li, Xin ; Luo, Chao-Bing

Technical alkaline lignin (TAL)-based composite films have been developed for anti-corrosion applications, during which one-component solvents, including acetone and ethanol, were employed. The poor solubility of TAL in the abovementioned solvents undoubtedly resulted in inhomogeneous surface micromorphology and the consequent unstable performance. The present study provides a series of ethylcellulose/TAL (EC/TAL) composite films with uniform surface microstructure by using the 1,4-dioxane/water binary solvent. EC/TAL film presents an excellent tensile stress of 26.4 MPa with an elongation at break of 26.8 %, which is better than those of EC film (18.4 MPa and 13.3 %). The addition of TAL significantly improves the thermostability of the composite films. The lignin component also contributes to the corrosion inhibition performances. In the 1 mol/L HCl electrolyte, the corrosion inhibition efficiency achieves 98.8 %, and these performances are all higher than 90 % in 3.5 wt% NaCl and 0.1 mol/L KOH solutions. All these results manifest that the 1,4-dioxane/water binary solvent can be used to form TAL-containing films. The performances of as-prepared films indicate their excellent potential as an anti-corrosion coating.

01 Nov 2024·Chemistry & Biodiversity

Contact Toxicity and Repellent Effects of Essential Oils from Toddalia asiatica Against Two Stored‐Product Insects

Article

Author: Wang, Jia‐Zhu ; Wang, Dan ; Zhang, Yu‐Chen ; Liu, Ao ; Qi, Yuan‐Tong ; Du, Shu‐Shan

AbstractInsect infestations continually endanger stored goods, underscoring the significance of discovering eco‐friendly insecticides for pest management. Essential oils (EOs) from different parts of Toddalia asiatica (leaf, fruit and branch) were extracted by hydrodistillation and analyzed by GC‐MS. Carvene, p‐cymene and muurolene are the principal compounds of T. asiatica leaf (TAL), T. asiatica fruit (TAF) and T. asiatica branch (TAB) EO respectively. Our work aimed to assess the contact toxicity and repellent effects of EOs on two storage pests, Tribolium castaneum and Lasioderma serricorne. All tested EOs exhibited obvious contact toxicity, especially, TAL EO against T. castaneum (33.48 μg/adult) and TAF EO against L. serricorne (16.42 μg/adult). Repellency tests revealed that TAL and TAF EOs, at a concentration of 78.63 nL/cm2, achieved nearing 100 % efficiency against T. castaneum. These results suggest that EOs of T. asiatica could be used as effective botanical insecticides for managing stored‐product insects.

01 Dec 2023·Biomedicine & Pharmacotherapy

Regulation of phosphosignaling pathways involved in transcription of cell cycle target genes by TRH receptor activation in GH1 cells

Article

Author: Novotny, Jiri ; Trubacova, Radka ; Drastichova, Zdenka

Thyrotropin-releasing hormone (TRH) is known to activate several cellular signaling pathway, but the activation of the TRH receptor (TRH-R) has not been reported to regulate gene transcription. The aim of this study was to identify phosphosignaling pathways and phosphoprotein complexes associated with gene transcription in GH1 pituitary cells treated with TRH or its analog, taltirelin (TAL), using label-free bottom-up mass spectrometry-based proteomics. Our detailed analysis provided insight into the mechanism through which TRH-R activation may regulate the transcription of genes related to the cell cycle and proliferation. It involves control of the signaling pathways for β-catenin/Tcf, Notch/RBPJ, p53/p21/Rbl2/E2F, Myc, and YY1/Rb1/E2F through phosphorylation and dephosphorylation of their key components. In many instances, the phosphorylation patterns of differentially phosphorylated phosphoproteins in TRH- or TAL-treated cells were identical or displayed a similar trend in phosphorylation. However, some phosphoproteins, especially components of the Wnt/β-catenin/Tcf and YY1/Rb1/E2F pathways, exhibited different phosphorylation patterns in TRH- and TAL-treated cells. This supports the notion that TRH and TAL may act, at least in part, as biased agonists. Additionally, the deficiency of β-arrestin2 resulted in a reduced number of alterations in phosphorylation, highlighting the critical role of β-arrestin2 in the signal transduction from TRH-R in the plasma membrane to transcription factors in the nucleus.

100 Deals associated with Talacotuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14796

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	-	CSL Ltd.	-
Acute Myeloid Leukemia	Phase 3	-	Janssen Global Services LLC	-
Acute Myeloid Leukemia	Preclinical	Germany	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	Spain	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	Sweden	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	Poland	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	Poland	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	Spain	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	Sweden	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	Germany	Janssen Biotech, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03011034 (CTgov)	Phase 2	Myelodysplastic Syndromes	34	Talacotuzumab (Talacotuzumab)	dbgvurmbss(syoodipgzv) = htskypczmf ajrbwxfsqw (lmvqbnwjus, rvunpuqwsv - iymxtotdtk) View more	-	13 Mar 2020
				Daratumumab (Daratumumab)	dbgvurmbss(syoodipgzv) = iivkdfygfd ajrbwxfsqw (lmvqbnwjus, bramgbjeri - zdxtcvpjji) View more
NCT02472145 (CTgov)	Phase 2/3	Acute Myeloid Leukemia	326	Decitabine (Part B: Decitabine (Alone))	dymphnxmev(poguuhdosq) = ixjkkwfixj dlrtwrzihb (ptdbfwqvqx, hqcbmrlppj - bpqjrvvlps) View more	-	28 Feb 2019
				Decitabine+JNJ-56022473 (Part B: Decitabine + JNJ-56022473)	dymphnxmev(poguuhdosq) = nuhvatkenm dlrtwrzihb (ptdbfwqvqx, xemqqyiohg - zdunvtatwh) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data